MX2019015246A - Oligonucleotidos antisentido de tirosinasa. - Google Patents
Oligonucleotidos antisentido de tirosinasa.Info
- Publication number
- MX2019015246A MX2019015246A MX2019015246A MX2019015246A MX2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A MX 2019015246 A MX2019015246 A MX 2019015246A
- Authority
- MX
- Mexico
- Prior art keywords
- tyrosinase
- human tyrosinase
- antisense oligonucleotides
- nucleic acid
- mrna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Abstract
Se proporcionan derivados de ácido nucleico peptídico con especificidad de objetivo contra un sitio de empalme 3' del pre-ARNm de tirosinasa humana. Los derivados de ácido nucleico peptídico inducen potencialmente una variante de empalme del ARNm de tirosinasa humana en células y son útiles para tratar de forma segura indicaciones o afecciones dermatológicas que implican la proteína tirosinasa humana tras la administración tópica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170093605 | 2017-07-24 | ||
KR1020170167558A KR20190011181A (ko) | 2017-07-24 | 2017-12-07 | 티로시나아제 안티센스 올리고뉴클레오티드 |
PCT/KR2018/008143 WO2019022434A1 (en) | 2017-07-24 | 2018-07-19 | ANTISENSE OLIGONUCLEOTIDES OF TYROSINASE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015246A true MX2019015246A (es) | 2020-07-20 |
Family
ID=65367910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015246A MX2019015246A (es) | 2017-07-24 | 2018-07-19 | Oligonucleotidos antisentido de tirosinasa. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230148418A1 (es) |
EP (1) | EP3658570B1 (es) |
JP (1) | JP7109532B2 (es) |
KR (1) | KR20190011181A (es) |
CN (1) | CN110831958B (es) |
AR (1) | AR112761A1 (es) |
AU (1) | AU2018308224B9 (es) |
BR (1) | BR112020000461A2 (es) |
CA (1) | CA3069570A1 (es) |
ES (1) | ES2906396T3 (es) |
MX (1) | MX2019015246A (es) |
SG (1) | SG11201912447RA (es) |
TW (1) | TWI782999B (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US20040215006A1 (en) * | 2003-04-25 | 2004-10-28 | Isis Pharmaceuticals Inc. | Modulation of tyrosinase expression |
US20050215506A1 (en) * | 2001-12-20 | 2005-09-29 | Bennett C F | Modulation of tyrosinase expression |
AR039007A1 (es) * | 2002-03-19 | 2005-02-02 | Monsanto Technology Llc | Acidos nucleicos y polipeptidos de homogentisato prenil transferasa (hpt) y usos de los mismos |
US7504385B2 (en) * | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
KR100569773B1 (ko) * | 2003-12-22 | 2006-04-10 | 한국전자통신연구원 | 이동통신 시스템의 프레임 구성 장치 및 프레임 구성 방법 |
CN101001868A (zh) * | 2004-06-17 | 2007-07-18 | 曼康公司 | 表位类似物 |
FR2890074B1 (fr) * | 2005-09-01 | 2007-11-23 | Lvmh Rech | Nouveaux oligonucleotides anti-genes specifiques de la tyrosinase comme agents depigmentants |
FR2909383B1 (fr) * | 2006-12-05 | 2009-04-17 | L V M H Rech Groupement D Inte | Nouveaux oligonucleotides et utilisation d'oligonucleotides interagissant avec le gene codant pour la tyrosinase related protein-1 (trp-1) pour en moduler son expression comme agents depigmentants. |
KR20090098710A (ko) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
US20190337987A1 (en) * | 2016-12-30 | 2019-11-07 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
-
2017
- 2017-12-07 KR KR1020170167558A patent/KR20190011181A/ko unknown
-
2018
- 2018-07-02 TW TW107122732A patent/TWI782999B/zh active
- 2018-07-19 JP JP2020503851A patent/JP7109532B2/ja active Active
- 2018-07-19 US US16/630,688 patent/US20230148418A1/en active Pending
- 2018-07-19 SG SG11201912447RA patent/SG11201912447RA/en unknown
- 2018-07-19 EP EP18837280.9A patent/EP3658570B1/en active Active
- 2018-07-19 CA CA3069570A patent/CA3069570A1/en active Pending
- 2018-07-19 AU AU2018308224A patent/AU2018308224B9/en active Active
- 2018-07-19 ES ES18837280T patent/ES2906396T3/es active Active
- 2018-07-19 CN CN201880043566.9A patent/CN110831958B/zh active Active
- 2018-07-19 MX MX2019015246A patent/MX2019015246A/es unknown
- 2018-07-19 BR BR112020000461-8A patent/BR112020000461A2/pt unknown
- 2018-07-23 AR ARP180102055A patent/AR112761A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201907958A (zh) | 2019-03-01 |
CN110831958A (zh) | 2020-02-21 |
ES2906396T3 (es) | 2022-04-18 |
AU2018308224B9 (en) | 2022-03-31 |
BR112020000461A2 (pt) | 2020-07-21 |
TWI782999B (zh) | 2022-11-11 |
SG11201912447RA (en) | 2020-02-27 |
AU2018308224A1 (en) | 2020-02-06 |
CN110831958B (zh) | 2023-07-04 |
AU2018308224B2 (en) | 2022-03-24 |
KR20190011181A (ko) | 2019-02-01 |
EP3658570B1 (en) | 2021-12-01 |
JP7109532B2 (ja) | 2022-07-29 |
US20230148418A1 (en) | 2023-05-11 |
EP3658570A1 (en) | 2020-06-03 |
AR112761A1 (es) | 2019-12-11 |
RU2019142512A (ru) | 2021-08-24 |
CA3069570A1 (en) | 2019-01-31 |
EP3658570A4 (en) | 2021-04-14 |
RU2019142512A3 (es) | 2021-11-08 |
JP2020528899A (ja) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
EP4349414A3 (en) | Methods and formulations for transdermal administration | |
WO2013059737A3 (en) | Tissue treatment device and related methods | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
EP3684353A4 (en) | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT | |
BR112019002387A2 (pt) | oligonucleotídeos antissenso de receptor de andrógeno | |
EP4166667A3 (en) | Compositions for modulating c9orf72 expression | |
MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
MX2019008445A (es) | Calmante de dolor scn9a antisentido. | |
WO2011082409A3 (en) | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 | |
NZ702967A (en) | Diclofenac formulations | |
CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
EA200970154A1 (ru) | Косметические или дерматологические препараты, содержащие n-ацетилцистеин | |
EP3818991A3 (en) | Compositions and methods for treating diseases | |
EA201891235A1 (ru) | Составы лекарственных средств для лечения злокачественной опухоли | |
BR112015004110A2 (pt) | sistemas e métodos de distribuição de drogas para tratamento de próstata | |
WO2014153385A3 (en) | Methods of treating metabolic disorders | |
BR112018012749A2 (pt) | composições para higiene pessoal | |
WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
PH12019502874A1 (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
WO2011124245A3 (de) | Mikrobiologisch stabile anwendungsfreundliche zubereitungen mit anionischen oder kationischen wirkstoffen | |
MX2019007903A (es) | Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25). | |
WO2016205397A3 (en) | Target-specific delivery of therapeutic agents |